Logo Logo Logo Logo Logo
  • COMPANY
    • ABOUT US
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • Contact Us
  • TECHNOLOGIES
    • OPTIREACH Technology
    • Antibody Fragment Technology
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
    • OCS-05 Glaucoma
  • NEWS
    • Press releases
    • Articles
  • CAREERS

  • COMPANY

    • ABOUT US
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • Contact Us

  • TECHNOLOGIES

    • OPTIREACH Technology
    • Antibody Fragment Technology

  • PIPELINE

    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
    • OCS-05 Glaucoma

  • NEWS

    • Press releases
    • Articles
  • CAREERS
Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech

...

10 September, 2020
Contact us

Oculis Switzerland
Corporate Headquarters
EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne
Switzerland

+41 21 711 3970

 

info@oculis.com

Copyright © 2022 Oculis SA.

 

    © Oculis – Privacy Policy – Terms of Use  – Cookie Policy    

    © L’autreagence 2019 – 2022